James Burks
Endocrinology, Diabetes & Metabolism · Odessa, TXNPI 1093803942
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 23.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,257 and has fallen 98.3% since, to $22 in 2023. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in TX, where the typical reported total is $2,974.
Across 152 payments — averaging $17.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$640
- Lilly USA, LLC$364
- Amgen$305
- Smith+Nephew$252
- Boehringer Ingelheim$225
- AstraZeneca$113
- plus $789 from 18 others
What the payments were for
- Food & beverage$2,683100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 51 | $640 |
| Lilly USA, LLC | 25 | $364 |
| Amgen(2 entities) | 15 | $305 |
| Smith+Nephew | 2 | $252 |
| Boehringer Ingelheim | 11 | $225 |
| AstraZeneca(2 entities) | 6 | $113 |
| Dexcom, Inc. | 6 | $103 |
| Corcept Therapeutics | 5 | $94 |
| Sanofi-aventis U.S. LLC | 5 | $90 |
| Tandem Diabetes Care, Inc. | 4 | $87 |
| Ultragenyx Pharmaceutical Inc. | 4 | $80 |
| Radius Health, Inc. | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 2 | $40 |
| Shire North American Group Inc | 2 | $38 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| Mannkind Corporation | 1 | $25 |
| Amryt Pharma Holdings Ltd | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $24 |
| Abbott | 1 | $24 |
| Echosens North America, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Medtronic | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CORI$137
- REAL INTELLIGENCE$115
How this compares
$2,688 in reported general payments places this provider in the 45th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methocarbamol | 21 | $105 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Odessa
- Anna VanderheidenOdessa$179K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.